Wall Street Skeptical of Novo Nordisk's Obesity Business Growth Despite Raised Forecast

Despite Novo Nordisk raising its forecast, Wall Street remains unconvinced about the sustainable growth path for its obesity business, citing intensifying competition from Eli Lilly.